

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) An anti-tumor agent comprising  
~~(a) a tubulin polymerization-inhibitory active substance having anti-tumor activity~~  
and one or more anti-inflammatory active ~~substance~~ substances selected from the group  
consisting of Dexamethasone, betamethasone, triamcinolone, paramethasone,  
beclomethasone, fluocinolone acetonide, and cortisol, wherein said and  
  
(b) a tubulin polymerization-inhibitory active substance having anti-tumor activity is  
selected from the group consisting of (Z)-N-[2-methoxy-5-[2-(3,4,5-  
trimethoxyphenyl)vinyl]phenyl]-L-serinamide or and a salt thereof.
2. – 4. (Canceled)
5. (Currently Amended) The anti-tumor agent according to ~~Claim 4~~ Claim 1, wherein  
the Dexamethasone ~~and derivatives thereof are~~ is selected from the group consisting of  
Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone.
6. – 10. (Canceled)
11. (Previously Presented) The anti-tumor agent according to Claim 1, wherein the  
tubulin polymerization-inhibitory active substance is (Z)-N-[2-methoxy-5-[2-(3,4,5-  
trimethoxyphenyl)vinyl]phenyl]-L-serinamide hydrochloride.
12. (Original) The anti-tumor agent according to Claim 1, wherein the tubulin  
polymerization-inhibitory active substance is in the form of an anti-tumor pharmaceutical

preparation and the anti-inflammatory active substance is in the form of an anti-inflammatory agent.

13. (Original) The anti-tumor agent according to Claim 12, wherein the anti-tumor pharmaceutical preparation and the anti-inflammatory agent are separately administered.

14. (Original) The anti-tumor agent according to Claim 1, wherein the tubulin polymerization-inhibitory active substance having anti-tumor activity is present in a unit dosage form at a quantity ranging from 0.1-10000mg.

15. (Original) The anti-tumor agent according to Claim 1, wherein the anti-inflammatory active substance is present in a unit dosage form at a quantity ranging from 0.1-10000mg

16. (Withdrawn; Currently Amended) A method for treatment of tumors, which comprises administering to a subject in need thereof a composition comprising

(a) an effective amount of a tubulin polymerization-inhibitory active substance having anti-tumor activity and an effective amount of one or more an anti-inflammatory active substance substances selected from the group consisting of Dexamethasone, betamethasone, triamcinolone, paramethasone, beclomethasone, fluocinolone acetonide, and cortisol, wherein said and

(b) an effective amount of a tubulin polymerization-inhibitory active substance having anti-tumor activity-is selected from the group consisting of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide or and a salt thereof.

17. (Withdrawn) The method according to Claim 16, wherein said subject in need thereof is a human.

18. (Withdrawn) The method according to Claim 16, wherein said effective amount of said tubulin polymerization-inhibitory active substance having anti-tumor activity ranges from 0.1-10000mg per day.

19. (Withdrawn) The method according to Claim 16, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.

20. – 21. (Canceled)

22. (Withdrawn; Currently Amended) A method for treatment of tumors, comprising administering to a subject in need thereof

(a) a composition comprising ~~and~~ an effective amount of a tubulin polymerization-inhibitory active substance having anti-tumor activity selected from the group consisting of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide and a salt thereof; and

(b) a composition comprising an effective amount of one or more anti-inflammatory active substances selected from the group consisting of Dexamethasone, betamethasone, triamcinolone, paramethasone, beclomethasone, fluocinolone acetonide, and cortisol ~~substance, wherein said tubulin polymerization-inhibitory active substance having anti-tumor~~

activity is ~~(Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide or a salt thereof.~~

23. (Withdrawn) The method according to Claim 22, wherein (a) and (b) are administered simultaneously or sequentially.

24. (Withdrawn) The method according to Claim 22, wherein said subject in need thereof is a human.

25. (Withdrawn) The method according to Claim 22, wherein said effective amount of said tubulin polymerization-inhibitory active substance having anti-tumor activity ranges from 0.1-10000mg per day.

26. (Withdrawn) The method according to Claim 22, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.

27. – 28. (Canceled)

29. (Original) A composition comprising (a) (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide, an ester thereof, or an salt thereof, and (b) dexamethasone, an ester thereof, or an salt thereof.

30. (Currently Amended) An anti-tumor agent comprising ~~one or more tubulin polymerization-inhibitory active substance having anti-tumor activity and~~

(a) an anti-inflammatory active substance, wherein the anti-inflammatory active substance is a Dexamethasone selected from the group consisting Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone; and

(b) one or more tubulin polymerization-inhibitory active substance having anti-tumor activity selected from the group consisting of combretastatines, vinca alkaloids, colchicinoids, dolastatins, podophyllotoxins, steganacins, amphethiniles, fiavonoids, rhizoxins, curacins A, epothilones A, epothilones B, welwistatins, phenstatins, 2-strylquinazoline-4(3H)-ones, stilbenes, 2-aryl-1,8-naphthyridin-4(1H)-ones, 5,6-dihydroindolo(2,1-a) isoquinolines, 2,3-benzo(b)thiophenes, 2,3-substituted benzo(b)furans, 2,3-substituted indoles, and 2-methoxyestradiol.

31. (Canceled)

32. (Currently Amended) The anti-tumor agent according to Claim 30, wherein the tubulin polymerization-inhibitory active substance is selected from the group consisting of combretastines ~~and derivatives thereof~~ and stilbenes ~~and derivatives thereof~~, and the anti-inflammatory active substance is ~~selected from the group consisting of Dexamethasone and derivatives thereof.~~

33. (Previously Presented) The anti-tumor agent according to Claim 30, wherein the tubulin polymerization-inhibitory active substance is (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide or salt thereof.

34. (Previously Presented) The anti-tumor agent according to Claim 30, wherein the tubulin polymerization-inhibitory active substance is (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide hydrochloride.

35. (Previously Presented) The anti-tumor agent according to Claim 30, wherein the tubulin polymerization-inhibitory active substance is in the form of an anti-tumor pharmaceutical preparation and the anti-inflammatory active substance is in the form of an anti-inflammatory agent.

36. (Previously Presented) The anti-tumor agent according to Claim 35, wherein the anti-tumor pharmaceutical preparation and the anti-inflammatory agent are separately administered.

37. (Previously Presented) The anti-tumor agent according to Claim 30, wherein the tubulin polymerization-inhibitory active substance having anti-tumor activity is present in a unit dosage form at a quantity ranging from 0.1-10000mg.

38. (Previously Presented) The anti-tumor agent according to Claim 30, wherein the anti-inflammatory active substance is present in a unit dosage form at a quantity ranging from 0.1-10000mg

39. (Currently Amended) A method for treatment of tumors, which comprises administering to a subject in need thereof a composition comprising ~~an effective amount of~~

~~one or more tubulin polymerization-inhibitory active substance having anti-tumor activity~~  
and

(a) an effective amount of an anti-inflammatory active substance, wherein the anti-inflammatory active substance is a Dexamethasone selected from the group consisting Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone; and

(b) one or more tubulin polymerization-inhibitory active substance having anti-tumor activity selected from the group consisting of combretastatines, vinca alkaloids, colchicinoids, dolastatins, podophyllotoxins, steganacins, amphethiniles, flavonoids, rhizoxins, curacins A, epothilones A, epothilones B, welwistatins, phenstatins, 2-strylquinazoline-4(3H)-ones, stilbenes, 2-aryl-1,8-naphthyridin-4(1H)-ones, 5,6-dihydroindolo(2,1-a) isoquinolines, 2,3-benzo(b)thiophenes, 2,3-substituted benzo(b)furans, 2,3-substituted indoles, and 2-methoxyestradiol.

40. (Previously Presented) The method according to Claim 39, wherein said subject in need thereof is a human.

41. (Previously Presented) The method according to Claim 39, wherein said effective amount of said tubulin polymerization-inhibitory active substance having anti-tumor activity ranges from 0.1-10000mg per day.

42. (Previously Presented) The method according to Claim 39, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.

43. (Canceled)

44. (Currently Amended) A method for treatment of tumors, comprising administering to a subject in need thereof

(a) a composition comprising an effective amount of one or more tubulin polymerization-inhibitory active substance having anti-tumor activity selected from the group consisting of combretastatines, vinca alkaloids, colchicinoids, dolastatins, podophyllotoxins, steganacins, amphethiniles, flavonoids, rhizoxins, curacins A, epothilones A, epothilones B, welwistatins, phenstatins, 2-strylquinazoline-4(3H)-ones, stilbenes, 2-aryl-1,8-naphthyridin-4(1H)-ones, 5,6-dihydroindolo(2,1-a) isoquinolines, 2,3-benzo(b)thiophenes, 2,3-substituted benzo(b)furans, 2,3-substituted indoles, and 2-methoxyestradiol; and

(b) a composition comprising an effective amount of an anti-inflammatory active substance, wherein the anti-inflammatory active substance is a Dexamethasone selected from the group consisting Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone.

45. (Previously Presented) The method according to Claim 44, wherein (a) and (b) are administered simultaneously or sequentially.

46. (Previously Presented) The method according to Claim 44, wherein said subject in need thereof is a human.

47. (Previously Presented) The method according to Claim 44, wherein said effective amount of said tubulin polymerization-inhibitory active substance having anti-tumor activity ranges from 0.1-10000mg per day.



48. (Previously Presented) The method according to Claim 44, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.

49. (Canceled)

SUPPORT FOR THE AMENDMENTS

Claims 2, 20, and 27 were previously canceled.

Claims 3, 4, 6-10, 21, 28, 31, 43, and 49 are canceled herein.

Claims 1, 5, 16, 22, 30, 32, 39, and 44 have been amended.

The amendment to Claims 1, 16, 22, 30, 39, and 44 are supported by previously pending Claims 4, 21, 28, 31, 43, and 49, respectively. Support for the amendment to Claims 5 and 32 is provided by the corresponding claims as previously presented.

No new matter has been added by the present amendment.